Carboplatin with nab-paclitaxel as first-line therapy in patients with advanced non-small-cell lung cancer and idiopathic interstitial pneumonias
Phase 2
- Conditions
- non-small-cell lung cancer with idiopathic interstitial pneumonias
- Registration Number
- JPRN-UMIN000026706
- Lead Sponsor
- Kurashiki Central Hospital Department of Respiratory medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
Not provided
Exclusion Criteria
1) with interstitial pneumonias secondary to other conditions 2) with history of acute exacerbations of interstitial pneumonias within 3 months 3) with history of subacute exacerbations of interstitial pneumonias within 3 months 4) with usage of immunosuppressants 5) with peripheral neuropathy with Grade 2-4 6) with allergy to carboplatin, albumin, or taxane-based anticancer agents 7) with active infectious diseases 8) with active double cancers 9) with clinically important complications 10) with positivity of HBs antigen
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate (not necessarily with confirmation)
- Secondary Outcome Measures
Name Time Method progression free survival, overall survival, time to treatment failure, response rate with confirmation, adverse events